- Diabetes, Obesity and Metabolism
- Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond
-
Adie Viljoen, Stephen C. Bain
-
Endocrinol Metab. 2023;38(1):25-33. Published online February 6, 2023
-
DOI: https://doi.org/10.3803/EnM.2022.1642
-
-
883
View
-
174
Download
-
1
Citations
-
 Abstract
 PDF PubReader  ePub  Crossref - TDM
- The therapeutic benefits of the incretin hormone, glucagon-like peptide 1 (GLP1), for people with type 2 diabetes and/or obesity, are now firmly established. The evidence-base arising from head-to-head comparative effectiveness studies in people with type 2 diabetes, as well as the recommendations by professional guidelines suggest that GLP1 receptor agonists should replace more traditional treatment options such as sulfonylureas and dipeptidyl-peptidase 4 (DPP4) inhibitors. Furthermore, their benefits in reducing cardiovascular events in people with type 2 diabetes beyond improvements in glycaemic control has led to numerous clinical trials seeking to translate this benefit beyond type 2 diabetes. Following early trial results their therapeutic benefit is currently being tested in other conditions including fatty liver disease, kidney disease, and Alzheimer’s disease.
-
Citations
Citations to this article as recorded by  - Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
John R. Ussher, Daniel J. Drucker
Nature Reviews Cardiology.2023;[Epub] CrossRef
|
KES
